UB Paderborn / Katalog / Suche / in CDI

26 – 50 von 139

Sortiert nach

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.826-850

2008

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Volltextzugriff (PDF)

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S74-S77

Leonardi, Craig L

2016

Volltextzugriff (PDF)

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4S), p.S74

Leonardi, Craig L

2016

Volltextzugriff (PDF)

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

JAMA : the journal of the American Medical Association, 2011-08, Vol.306 (8), p.864

2011

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.851-864

2008

Volltextzugriff (PDF)

New and emerging therapies in psoriasis

Seminars in cutaneous medicine and surgery, 2014-03, Vol.33 (2 Suppl 2), p.S37-S41

2014

Volltextzugriff (PDF)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

Advances in therapy, 2022-05, Vol.39 (5), p.2256-2269

2022

Volltextzugriff (PDF)

Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Journal of the American Academy of Dermatology, 2020-02, Vol.82 (2), p.519-522

2020

Volltextzugriff (PDF)

Small Molecules for Psoriasis

Seminars in cutaneous medicine and surgery, 2016-06, Vol.35 (4 Suppl 4), p.S65-S66

Leonardi, Craig L

2016

Volltextzugriff (PDF)

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Journal of the American Academy of Dermatology, 2021-02, Vol.84 (2), p.398-407

2021

Volltextzugriff (PDF)

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2021-03, Vol.35 (2), p.229-238

2021

Volltextzugriff (PDF)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

American journal of clinical dermatology, 2018-06, Vol.19 (3), p.437-447

2018

Volltextzugriff (PDF)

Data on the safety of psoriasis therapies

Seminars in cutaneous medicine and surgery, 2014-06, Vol.33 (4 Suppl), p.S73-S75

Leonardi, Craig L

2014

Volltextzugriff (PDF)

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

Journal of the American Academy of Dermatology, 2009-07, Vol.61 (1), p.S1-S46

2009

Volltextzugriff (PDF)

Therapeutic development in psoriasis

Seminars in cutaneous medicine and surgery, 2014-06, Vol.33 (4 Suppl), p.S69-S72

2014

Volltextzugriff (PDF)

Serious adverse events-Missing in action: Comment on the article by Kremer et al

Arthritis & rheumatology (Hoboken, N.J.), 2012-09, Vol.64 (9), p.3055-3056

Leonardi, Craig L.

2012

Volltextzugriff (PDF)

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR

Drug safety, 2021-06, Vol.44 (6), p.699-709

2021

Volltextzugriff (PDF)

Etanercept as Monotherapy in Patients with Psoriasis

The New England journal of medicine, 2003-11, Vol.349 (21), p.2014-2022

2003

Volltextzugriff (PDF)

Subgroup analyses of etanercept in pediatric patients with psoriasis

Journal of the American Academy of Dermatology, 2010-08, Vol.63 (2), p.e38-e41

2010

Volltextzugriff (PDF)

Efalizumab: an overview

Journal of the American Academy of Dermatology, 2003-08, Vol.49 (2), p.98-104

Leonardi, Craig L

2003

Volltextzugriff (PDF)

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Journal of the American Academy of Dermatology, 2005-03, Vol.52 (3), p.425-433

2005

Volltextzugriff (PDF)

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Journal of drugs in dermatology, 2016-05, Vol.15 (5), p.562

2016

Volltextzugriff (PDF)

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Journal of drugs in dermatology, 2013-08, Vol.12 (8), p.888

2013

Volltextzugriff (PDF)

Ten years on: the impact of biologics on the practice of dermatology

Dermatologic clinics, 2015-01, Vol.33 (1), p.111-125

2015

Volltextzugriff (PDF)

26 – 50 von 139

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(102)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Dermatology
(84)
Humans
(83)
Life Sciences & Biomedicine
(83)
Psoriasis - Drug Therapy
(52)
Psoriasis
(44)
Female
(42)
Male
(42)
Biological And Medical Sciences
(41)
Medical Sciences
(41)
Middle Aged
(35)
Adult
(33)
Treatment Outcome
(29)
Severity Of Illness Index
(27)
Psoriasis. Parapsoriasis. Lichen
(24)
Antibodies, Monoclonal - Therapeutic Use
(21)
Double-Blind Method
(19)
Aged
(18)
Antibodies, Monoclonal - Adverse Effects
(18)
Antibodies, Monoclonal - Administration & Dosage
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

New and emerging therapies in psoriasis

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Small Molecules for Psoriasis

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

Data on the safety of psoriasis therapies

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach

Therapeutic development in psoriasis

Serious adverse events-Missing in action: Comment on the article by Kremer et al

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR

Etanercept as Monotherapy in Patients with Psoriasis

Subgroup analyses of etanercept in pediatric patients with psoriasis

Efalizumab: an overview

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

Reduction in C-Reactive-Protein Levels With Adalimumab Therapy in Patients With Moderate-to-Severe Hand and/or Foot Psoriasis

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study

Ten years on: the impact of biologics on the practice of dermatology

Aktive Filter

Suchergebnisse filtern